Piramal Pharma Completes Acquisition of Kenalog® from Bristol-Myers Squibb

Piramal Pharma Completes Acquisition of Kenalog® from Bristol-Myers Squibb​

Piramal Pharma Limited announced the successful completion of its acquisition of Kenalog® and related brands from Bristol-Myers Squibb Company. The acquisition was finalized by Piramal Critical Care B.V., a wholly-owned subsidiary of Piramal Pharma Limited.

This acquisition strengthens Piramal Pharma’s Complex Hospital Generics portfolio and expands its presence across key markets including the United States, Europe, and Asia Pacific. The initial announcement regarding the transaction was made on January 28, 2026.

Source:​

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.